Perimeter's B-Series OCT With ImgAssist AI 2.0 Set for Presentation at 2025 ASBrS Annual Meeting

Perimeter Medical's Pivotal Trial: A Transformative Leap in Breast Cancer Surgery

Perimeter Medical Imaging AI, Inc., a notable player in medical technology, has made significant strides in the field of breast cancer surgery. The company recently announced that it has been granted the opportunity to present detailed findings from its pivotal B-Series Optical Coherence Tomography (OCT) trial featuring ImgAssist AI 2.0 at the esteemed 26th Annual Meeting of the American Society of Breast Surgeons (ASBrS). This significant event will take place from April 30 to May 4, 2025, in Las Vegas, Nevada.

In recent months, Perimeter has generated considerable excitement within the medical community, announced that their pivotal clinical trial met its primary endpoint. This trial demonstrated a statistically significant decrease in the rate of patients experiencing residual cancer during surgery. Specifically, the trial achieved a p-value of 0.0050, highlighting the efficacy of their innovative technology in improving surgical outcomes.

The ASBrS serves as an important platform for breast surgery professionals, promoting excellence and continual improvement in the care of patients affected by breast disease. The pivotal findings shared at this conference are anticipated to include results previously reported alongside additional analyses concerning secondary endpoints.

Leading the discussion will be Dr. Alastair Thompson, the trial's Principal Investigator and a prominent figure in the breast surgical arena, who serves as Professor and Section Chief of Breast Surgery at Baylor College of Medicine. His involvement underscores the trial's significance and the rigor behind the research methodology employed.

Adrian Mendes, the CEO of Perimeter, voiced his enthusiasm regarding the upcoming presentation, expressing gratitude for the ASBrS's recognition of their work. Mendes remarked, “Being selected by the ASBrS is a tremendous honor. We are dedicated to advancing our AI-enabled OCT system in the United States.” The integration of advanced AI technology is poised to facilitate surgeons' utilization of the Perimeter B-Series, which offers a revolutionary way to visualize margins in real-time during operations.

Back in November 2024, Perimeter revealed promising topline results from the study, which are expected to support their application for premarket approval with the FDA. The company plans to submit this critical application in early 2025, marking a pivotal moment for the wide-scale adoption of their technology in the U.S.

Perimeter Medical Imaging AI, headquartered in Toronto and Dallas, aims to reshape the landscape of cancer surgery by developing ultra-high-resolution, real-time imaging solutions. Their existing Perimeter S-Series OCT system is FDA-cleared and offers cross-sectional visualization of excised tissue, enhancing surgical accuracy at the cellular level. The B-Series, recognized as a breakthrough device, is currently being tested in clinical settings supported by a generous grant from the Cancer Prevention and Research Institute of Texas.

It’s essential to note that the Perimeter B-Series OCT remains investigational and is not available for commercial sale within the United States. Nevertheless, the groundwork laid by their advanced research sets the stage for potential future breakthroughs in breast imaging and surgical precision. As they prepare for the ASBrS meeting, anticipation builds within both the medical community and patients alike concerning the future of breast cancer treatment.

In conclusion, the 2025 ASBrS Annual Meeting promises to be a pivotal event for Perimeter Medical Imaging AI, with the potential to elevate the conversation around innovative surgical technologies and significantly impact breast cancer surgery practices. As the company strives towards regulatory approval, the insights shared at this gathering will undoubtedly shape the trajectory of breast cancer treatment moving forward.